New pain drug could cut opioid use after tummy tucks
NCT ID NCT07102459
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 41 times
Summary
This study tested an experimental drug called LTG-001 for managing pain after a tummy tuck (abdominoplasty). 343 adults took either a high or low dose of LTG-001, a standard painkiller combination, or a placebo. Researchers measured pain relief over 48 hours and tracked how much extra opioid pain medication was needed. The goal was to see if LTG-001 works and is safe for short-term post-surgical pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PAIN are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Arizona Research Center
Phoenix, Arizona, 85053, United States
-
CenExel ACMR
Atlanta, Georgia, 30331, United States
-
Endeavor Clinical Research
San Antonio, Texas, 78240, United States
-
HD Research LLC
Houston, Texas, 77043, United States
-
JBR Clinical Research (CenExel)
Salt Lake City, Utah, 84107, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LTG-001 (an experimental painkiller)
What this could lead to
If it works, this could provide a new option for managing short-term pain after surgery, possibly reducing the need for opioid painkillers.
What could go wrong
This is an early Phase 2 trial, so results may not confirm effectiveness or safety. The drug is only tested for 48 hours after one type of surgery, so it may not work for other pain types or longer periods.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.